Royalty Report: Medical, Cancer, Diagnostic – Collection: 89818


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Medical
  • Cancer
  • Diagnostic
  • Device
  • Disease
  • Technical Know How
  • Test/Monitoring
  • Drugs
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 89818

License Grant
The company entered into a license agreement with a party pursuant to which the company granted the party an exclusive license to manufacture, sell and distribute LuViva in Taiwan, Brunei, Darussalam, Cambodia, Laos, Myanmar, Philippines, Singapore, Thailand, and Vietnam.   The party was already our exclusive distributor in China, Macau and Hong Kong, and the license extends to manufacturing in those countries as well. Under the terms of the license agreement, once the party is capable of manufacturing LuViva in accordance with ISO 13485 for medical devices, the Licensee will pay a royalty of the distributor price (subject to a discount under certain circumstances), whichever is higher, per disposable distributed within the Licensee’s exclusive territories.
License Property
LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.  LuViva provides a less invasive and painless alternative to conventional tests for cervical cancer screening and detection.
Field of Use
This agreement pertains to the medical industry relating to medical devices for detection of cancers.

IPSCIO Record ID: 815

License Grant
The Parties desire to fully and finally settle all disputes between them; now therefore, for and in consideration of the mutual covenants and agreements set forth herein.
License Property
The Parties have terminated their 2005 Agreement.
Field of Use
Any disposables sold by the Licensee to be used in conjunction with the Licensee's biophotonic cervical cancer and cervical pre-cancer detection device.

IPSCIO Record ID: 65577

License Grant
The Licensor receives quarterly royalty payments on the Licensees sales of products using licensed technology in the field of biophotonic technology.
License Property
The technology primarily relates to the use of biophotonics for the non-invasive detection of cancer and other diseases. Biophotonicsuses light (photons) to image, detect and manipulate biological materials.
Field of Use
The Licensee licenses, develops and commercializes non-invasive biophotonic technologies.

IPSCIO Record ID: 240571

License Grant
Licensor hereby grants the Japanese Licensee the sole and exclusive worldwide license under the Licensed Patents to (a) make, have made, use, sell, offer to sell, lease or otherwise dispose of Licensed Products in the Field; (b) practice a Licensed Methods in the Field; and (c) sell products or parts for use in practicing a Licensed Methods in the Field.
License Property
United States Patents
5,858,683 – Methods and compositions for the detection of cervical cancer
6,027,905 – Methods for the detection of cervical cancer
Field of Use
Field shall mean the field of detecting and assessing cervical cancer including screening using a nonslide-based format, but specifically excludes detecting and assessing cervical cancer in a slide-based format.

IPSCIO Record ID: 28487

License Grant
The Licensor granted the Licensee a non-exclusive license agreement for the use of the patent rights and technology as they relate to cervical and ovarian cancer.
License Property
The Company agreed to settle an arbitration proceeding instituted by anther party against the Company through the transfer to the other party of certain patents, patent applications and other intellectual property rights relating to the AcCell technology.

The AcCell product is a computer-aided automated microscopy instrument designed to help medical specialists examine and diagnose specimens of human cells.

U.S. Patent 6,535,626; 6,430,309; 6,285,498; 6,148,096; 6,151,161; 6,118,581; 6,091,842; 6,081,740; 5,999,844; 5,963,368; 5,930,732; 5,833,794; 5,690,892; 5,077,806; 5,073,857

Field of Use
Licensed Field shall mean the field of products designed, developed, tested, manufactured, distributed, marketed, approved, sold, provided, and/or used exclusively for the screening of cervical or ovarian cancer which require the incorporation of  a fluorescent probe as its primary probe,  or which may incorporate other fluorescent or non-fluorescent probes, and in which the assay itself (a procedure employing one or more reagents which determines the biological state of a clinical specimen comprised of cells or tissues) is primarily fluorescent.

Licensee have designed and manufactured the AcCell(TM) computer-aided automated microscopy instrument and the AcCell Savant(TM), an instrument that includes an AcCell instrument and software and which collects quantitative cellular information used in support of a diagnostic process.

Licensee is a life sciences company engaged in the design, development and commercialization of cost-effective screening systems to assist in the early detection of cancer.

IPSCIO Record ID: 27476

License Grant
The Licensor granted the Licensee, a long-time partner,  the exclusive rights to sell the products in China provided that the Licensee achieves local regulatory approvals within a 3-year period and does not export from China.
License Property
The Licensor is developing, testing and commercializing its non-invasive lung cancer risk test. The Electro Pulmonary Nodule Scan is a bioconductance measurement method to evaluate the risk of lung cancer in patients with lesions of the lung in well-controlled clinical trials.

The EPN Scan device is designed to provide further information on whether a lung legion may be cancerous after detection by CT Scan.

Field of Use
In February 2014, the Chinese licensee received approval to manufacture, but not market or sell, the device in China as a lung cancer risk stratification device.  On March 15, 2015 the licensee entered clinical trials at two prominent hospitals for the purpose of seeking approval to market and sell the EPN Scanner in China.

IPSCIO Record ID: 233450

License Grant
The Parties intend to develop in Asia a therapeutic product containing glufosfamide for the treatment of cancer.

The Japanese Licensor grants an exclusive license to Licensors Know-How to make, have made, use, offer to sell, sell and import Compound Product throughout the world.

License Property
The Compound shall mean glufosfamide.

The Compound Product shall mean any product that was developed by Licensee or a sublicensee of Licensee for marketing as a therapeutic that contains the Compound and that is for the treatment of cancer.

Field of Use
The Field shall mean all human cancer therapeutic uses.

IPSCIO Record ID: 391427

License Grant
The Australian Licensor, the Parent of the Licensee, hereby grants to Licensee a non-transferable, non-assignable, non-sublicensable, royalty-bearing and fee-bearing, limited license during the Term, in accordance with the terms and conditions of this Agreement under (1) the Licensed Rights and (2) Licensor’s ownership and legally enforceable rights in Biosensor, solely
a. to act as the regulatory authorisation holder for the purpose of, prosecuting the application of, and obtaining any, Regulatory Approval, including, being authorized to carry out any one or more Investigation for the purpose of (a) seeking approval from the relevant Regulatory Authorities to prosecute any approval for an Investigational Device to be used by an End User; and (b) applying for an IDE, including, obtaining approval for the Investigational Device to be shipped lawfully for the purpose of conducting Investigations for that Investigational Device, with an objective to submit such Investigations to the Regulatory Authority for Regulatory Approval.
The License is granted as an exclusive license in the Territory.
License Property
Technology related to measuring, or otherwise determining, the following (a) the amount or concentration of glucose; (b) the existence of biological markers of cancer; and (c) allergy/ immunology and hormones, each in a bodily fluid (e.g., saliva, blood) (each an “Indicator” and collectively the “Indicators”).

The Licensed Product comprises a product using the Organic Thin Film Technology, the Biosensor Technology encompassing but not limited to
a biosensor strip for one or more Indicator, including glucose Indicators; and

a proprietary smartphone application for the purpose reading, storing, analyzing and providing patient support programs for any one or more of the Indicators; and/or

a dedicated sensor strip reading device that is derived from the Licensed Rights.

Licensed Rights
1. The invention(s) described in PCT/AU2013/000207 and associated patent applications Australian provisional patent application 2012900885; PCT/AU2013/000207; Chinese patent application 201380022888.2; US patent application 14/382927;

2. The invention(s) described in the publication ‘printable organic thin film transistors for glucose detection incorporating ink jet printing of the enzyme recognition element, and the invention(s) described in PCT/AU2016/050555 and associated patent applications PCT/AU2016/050555 and the National Phase applications it will ultimately produce; and

3. all project intellectual property within the field,

Licensed Trademarks
Common law trade mark ‘Glucose Biosensor’

Field of Use
Licensee's flagship product is the Saliva Glucose Biosensor, a POCT expected to substitute the finger pricking invasive blood glucose monitoring for diabetic patients.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.